Pyxis Oncology PYXS
NASDAQ PYXS
$3.08 -0.04 (-1.28%)
At close: Aug 21, 2026 · 4:00 PM EDT

Pyxis Oncology (PYXS) Long-Term Deferred Tax (2021 - 2023)

Pyxis Oncology (PYXS) posted quarterly Long-Term Deferred Tax of $127.1 million for Q4 2023, up 106.75% year-over-year from $61.5 million in Q4 2022, and up 106.75% quarter-over-quarter from $61.5 million in Q4 2022.

Pyxis Oncology (PYXS) Long-Term Deferred Tax (2021 - 2023) Analysis & Trends

Pyxis Oncology (PYXS) has reported Long-Term Deferred Tax for 3 consecutive years, with $127.1 million the latest figure, recorded in Q4 2023.

  • In Q4 2023, Long-Term Deferred Tax rose 106.75% year-over-year to $127.1 million; the TTM figure through Dec 2023 stood at $127.1 million (up 106.75% YoY), while the FY2023 annual figure was $127.1 million, up 106.75% from the prior year.
  • Long-Term Deferred Tax rose to $127.1 million in Q4 2023 per PYXS's latest filing, from $61.5 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $127.1 million in Q4 2023 and bottomed at $3.5 million in Q3 2021.
  • Historically, Long-Term Deferred Tax has averaged $64.0 million across 3 years, with a median of $61.5 million in 2022.
  • On a YoY basis, Long-Term Deferred Tax climbed as much as 106.75% in 2023 and fell as far as 106.75% in 2023.
  • Pyxis Oncology's Long-Term Deferred Tax stood at $3.5 million in 2021, then jumped by 1656.24% to $61.5 million in 2022, then jumped by 106.75% to $127.1 million in 2023.
  • Business Quant data shows PYXS's Long-Term Deferred Tax at $127.1 million in Q4 2023, $61.5 million in Q4 2022, and $3.5 million in Q3 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Pyxis Oncology 198.37 Mn 165.38 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 127.12 Mn
Dec 31, 2022 61.49 Mn
Sep 30, 2021 3.50 Mn